fbpx

QQQ
+ 2.82
369.83
+ 0.76%
BTC/USD
+ 2082.87
64092.71
+ 3.36%
DIA
+ 1.93
350.57
+ 0.55%
SPY
+ 3.40
443.79
+ 0.76%
TLT
-2.01
147.72
-1.38%
GLD
+ 0.56
164.36
+ 0.34%

Tilray Analysts On The Sidelines Despite Solid Earnings

February 18, 2021 12:47 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Tilray Analysts On The Sidelines Despite Solid Earnings

Canadian cannabis companies Tilray Inc. (NASDAQ:TLRY) and Aphria Inc. (NASDAQ:APHA) have agreed to a merger.

Meanwhile, Tilray announced strong fourth-quarter results, with meaningful revenue growth and margin expansion.

The Tilray Analysts:

  • Michael Lavery of Piper Sandler downgraded the rating from Overweight to Neutral, while raising the price target from $15 to $26.
  • Scott Fortune of Roth Capital Partners maintained a Neutral rating, while raising the price target to $25.
  • Pablo Zuanic of Cantor Fitzgerald maintained a Neutral rating and a price target of $30.25.
  • See also: How to Buy Tilray Here (ACB) Stock 

The Tilray Thesis: “We believe Tilray's announced merger with Aphria can help build its scale and benefits from medical sales growth in the EU," Lavery wrote in the downgrade note. "We expect better profitability, helped by contributions from Aphria, deal synergies, and growth in higher-margin international medical sales."

Lavery expects US marijuana to be "federally permissible" within one to two years, and as a result, there is still "little visibility on Tilray's path to enter US THC markets."

With Tilray’s shares up 280% year to date, “we do not see upside to current valuation,” he added.

Commenting on Tilray’s fourth-quarter results, Fortune wrote, “We are encouraged by the 25% growth in cannabis sales which saw strength from Germany, and the international segment contribute 23% of 2020 sales. We see upside in the model from a cost savings standpoint if the announced merger with Aphria goes smoothly, but maintain Neutral on a challenging Canadian market and valuation.”

“Based on better-than-expected 4Q cannabis trends (sales and EBITDA), we could view the PT more positively, but we prefer to leave it unchanged until the 10-K is out and we have seen Hifyre scanner data for all of February. We continue to see upside from the merger, but we think APHA is the beer vehicle for investment in the future combined entity,” Zuanic noted.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Canadian Cannabis Producers Are Dependent On Value Flower: Analyst

Canadian Cannabis Producers Are Dependent On Value Flower: Analyst

Canadian licensed cannabis producers have been faced with challenges imposed by ongoing price deflation, COVID-19 lockdowns and uncertainty over whether and when U.S. federal legalization will occur. As a result, some Canadian cannabis companies have become dependent on value flower, according to a Cantor Fitzgerald analyst.  read more
Canadian Cannabis: Why This Penny Stock Is 'Arguably The Best Value'

Canadian Cannabis: Why This Penny Stock Is 'Arguably The Best Value'

Top Canadian cannabis stocks, including Tilray Inc (NASDAQ: TLRY), Aphria Inc (NASDAQ: APHA) and Aurora Cannabis Inc (NYSE: ACB), hav read more
Why This Organigram Analyst Says It's A Good Time To Buy Cannabis Stock

Why This Organigram Analyst Says It's A Good Time To Buy Cannabis Stock

Cannabis company Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI) posted second-quarter earnings last week, with gross reve read more
Cannabis Analyst: March Earning Season May Not Push Canadian LPs, But There Are Other Catalysts

Cannabis Analyst: March Earning Season May Not Push Canadian LPs, But There Are Other Catalysts

The global pandemic and following lockdowns impacted almost every sector of the economy. And the Canadian cannabis industry was no exception. read more